Krystal Bergin

539 total citations
29 papers, 348 citations indexed

About

Krystal Bergin is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Krystal Bergin has authored 29 papers receiving a total of 348 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hematology, 20 papers in Molecular Biology and 12 papers in Oncology. Recurrent topics in Krystal Bergin's work include Multiple Myeloma Research and Treatments (26 papers), Protein Degradation and Inhibitors (13 papers) and Peptidase Inhibition and Analysis (8 papers). Krystal Bergin is often cited by papers focused on Multiple Myeloma Research and Treatments (26 papers), Protein Degradation and Inhibitors (13 papers) and Peptidase Inhibition and Analysis (8 papers). Krystal Bergin collaborates with scholars based in Australia, New Zealand and United States. Krystal Bergin's co-authors include Andrew Spencer, Elizabeth Moore, Zoe McQuilten, Erica M. Wood, Anna Kalff, Simon J. Harrison, Patricia Walker, Paul Cameron, Michelle K. Yong and Sharon R. Lewin and has published in prestigious journals such as Blood, The Journal of Infectious Diseases and Frontiers in Immunology.

In The Last Decade

Krystal Bergin

28 papers receiving 344 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Krystal Bergin Australia	11	222	176	125	67	44	29	348
Rebeca Rodríguez‐Veiga Spain	10	171 0.8×	147 0.8×	117 0.9×	36 0.5×	21 0.5×	39	326
Scott Portwood United States	8	116 0.5×	191 1.1×	91 0.7×	41 0.6×	60 1.4×	16	326
Alun Parsons Finland	10	152 0.7×	174 1.0×	53 0.4×	25 0.4×	44 1.0×	18	304
Naomi Kawashima Japan	8	260 1.2×	129 0.7×	98 0.8×	34 0.5×	28 0.6×	37	369
Hiroyoshi Kunimoto Japan	9	205 0.9×	183 1.0×	41 0.3×	70 1.0×	50 1.1×	23	425
Daiki Karigane Japan	10	140 0.6×	128 0.7×	50 0.4×	67 1.0×	33 0.8×	31	337
Emily Heath Germany	4	103 0.5×	89 0.5×	88 0.7×	43 0.6×	29 0.7×	6	241
Manon Queudeville Germany	10	85 0.4×	97 0.6×	135 1.1×	51 0.8×	22 0.5×	27	332
Lindsay Hladnik United States	8	278 1.3×	129 0.7×	217 1.7×	50 0.7×	21 0.5×	12	482
Fabio Guolo Italy	10	112 0.5×	78 0.4×	127 1.0×	37 0.6×	28 0.6×	46	306

Countries citing papers authored by Krystal Bergin

Since Specialization

Citations

This map shows the geographic impact of Krystal Bergin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Krystal Bergin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Krystal Bergin more than expected).

Fields of papers citing papers by Krystal Bergin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Krystal Bergin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Krystal Bergin. The network helps show where Krystal Bergin may publish in the future.

Co-authorship network of co-authors of Krystal Bergin

This figure shows the co-authorship network connecting the top 25 collaborators of Krystal Bergin. A scholar is included among the top collaborators of Krystal Bergin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Krystal Bergin. Krystal Bergin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reynolds, John, Hang Quach, Anne Hutchinson, et al.. (2024). Response adaptive salvage treatment with daratumumab–lenalidomide–dexamethasone for newly diagnosed transplant‐eligible multiple myeloma patients failing front‐line bortezomib‐based induction therapy—ALLG MM21. British Journal of Haematology. 205(3). 900–914. 1 indexed citations

Turner, Rose, et al.. (2022). The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice. Frontiers in Oncology. 12. 820605–820605. 4 indexed citations

McQuilten, Zoe, Cameron Wellard, Elizabeth Moore, et al.. (2022). Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). British Journal of Haematology. 198(5). 830–837. 13 indexed citations

Bergin, Krystal, et al.. (2021). A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16‐02 trial. British Journal of Haematology. 194(3). 580–586. 6 indexed citations

Bergin, Krystal, Cameron Wellard, Bradley Augustson, et al.. (2021). Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR). Bone Marrow Transplantation. 56(10). 2533–2543. 9 indexed citations

Bergin, Krystal, Cameron Wellard, Elizabeth Moore, et al.. (2021). The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR). Clinical Lymphoma Myeloma & Leukemia. 21(6). e510–e520. 11 indexed citations

Mithraprabhu, Sridurga, Tiffany Khong, Anna Kalff, et al.. (2019). Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients. Leukemia. 33(8). 2022–2033. 46 indexed citations

Ho, P. Joy, Elizabeth Moore, Zoe McQuilten, et al.. (2019). Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry. Clinical Lymphoma Myeloma & Leukemia. 19(8). e415–e424. 17 indexed citations

Chua, Chong Chyn, Hui Yin Lim, Khai Li Chai, et al.. (2018). Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma. Bone Marrow Transplantation. 53(9). 1116–1123. 11 indexed citations

10.

Löw, Michael, Pasquale L. Fedele, Anna Kalff, et al.. (2018). DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma. Leukemia & lymphoma. 59(12). 2842–2846. 12 indexed citations

11.

Yong, Michelle K., Paul Cameron, Monica A. Slavin, et al.. (2017). Identifying Cytomegalovirus Complications Using the Quantiferon-CMV Assay After Allogeneic Hematopoietic Stem Cell Transplantation. The Journal of Infectious Diseases. 215(11). 1684–1694. 59 indexed citations

12.

Nair, Anish, Patricia Walker, Anna Kalff, et al.. (2017). Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma. Bone Marrow Transplantation. 52(6). 839–845. 4 indexed citations

13.

Spencer, Andrew, Simon J. Harrison, Jeffrey A. Zonder, et al.. (2017). A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (NPI‐0052‐107): final study results. British Journal of Haematology. 180(1). 41–51. 60 indexed citations

14.

Yong, Michelle K., Paul Cameron, Monica A. Slavin, et al.. (2017). Low T-Cell Responses to Mitogen Stimulation Predicts Poor Survival in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Immunology. 8. 1506–1506. 15 indexed citations

15.

Bergin, Krystal, Elizabeth Moore, Zoe McQuilten, et al.. (2016). Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry. BMC Medical Research Methodology. 16(1). 151–151. 22 indexed citations

16.

Bergin, Krystal, Adam C. Smith, Alina S. Gerrie, et al.. (2016). Clonal evolution as detected by interphase fluorescence in situ hybridization is associated with worse overall survival in a population-based analysis of patients with chronic lymphocytic leukemia in British Columbia, Canada. Cancer Genetics. 210. 1–8. 3 indexed citations

17.

Spencer, Andrew, Simon J. Harrison, Jacob P. Laubach, et al.. (2016). Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study. Blood. 128(22). 3326–3326. 7 indexed citations

18.

Bergin, Krystal, Zoe McQuilten, Elizabeth Moore, Erica M. Wood, & Andrew Spencer. (2016). Myeloma in the Real World: What Is Really Happening?. Clinical Lymphoma Myeloma & Leukemia. 17(3). 133–144.e1. 27 indexed citations

19.

Kalff, Anna, Sridurga Mithraprabhu, Tiffany Khong, et al.. (2016). A 2-Stage Phase II Study of Panobinostat Consolidation in Multiple Myeloma (MM) Patients with < CR Following Single High-Dose Chemotherapy (HDT) Conditioned Autologous Stem Cell Transplantation (ASCT) As Part of First Line Therapy. Blood. 128(22). 4515–4515. 1 indexed citations

20.

Kalff, Anna, Kate Reed, Tiffany Khong, et al.. (2015). Roar: A Phase Ib Trial of Oral Azacitidine in Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma (MM) Patients Refractory to Prior Lenalidomide. Blood. 126(23). 3033–3033.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact